Compare INM & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INM | VTAK |
|---|---|---|
| Founded | 1981 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.1M |
| IPO Year | N/A | 2018 |
| Metric | INM | VTAK |
|---|---|---|
| Price | $1.24 | $1.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 145.5K | 53.4K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,798,116.00 | $730,000.00 |
| Revenue This Year | N/A | $822.86 |
| Revenue Next Year | N/A | $168.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 82.96 |
| 52 Week Low | $1.13 | $1.49 |
| 52 Week High | $8.27 | $15.68 |
| Indicator | INM | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 40.23 |
| Support Level | $1.18 | $1.70 |
| Resistance Level | $1.35 | $3.06 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 28.13 | 11.03 |
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.